Zobrazeno 1 - 10
of 14
pro vyhledávání: '"S. B. Haugaard"'
Publikováno v:
European Heart Journal. 42
Background Low grade inflammation (LGI) is significantly associated with microvascular complications in diabetes mellitus (DM). Reduced and impaired Heart rate variability (HRV) is a strong marker of autonomic dysfunction and neuropathy and strongly
Autor:
S. B. Haugaard, Ole Kæseler Andersen, Birgitte Rønde Hansen, J E B Jensen, L Andresen, Johan Iversen, Frank Krieger Jensen
Publikováno v:
HIV Medicine. 11:266-275
Objectives The aim of the study was to investigate the effect of long-term high-physiological-dose recombinant human growth hormone (rhGH) therapy on fat distribution and glucose metabolism in HIV-infected patients. Methods Forty-six HIV-infected Cau
Autor:
Thorkil Ploug, S. B. Haugaard, Flemming Dela, Christina Neigaard Hansen, Sten Madsbad, Rasmus Rabøl, T. Almdal, Robert Boushel, Clara Prats
Publikováno v:
Diabetes, Obesity and Metabolism. 12:806-814
Aim Skeletal muscle insulin resistance has been linked to mitochondrial dysfunction. We examined how improvements in muscular insulin sensitivity following rosiglitazone (ROSI) or pioglitazone (PIO) treatment would affect muscle mitochondrial functio
Publikováno v:
Gene Expression to Genetical Genomics. 2:1-27
Glycogen synthase kinase 3β (GSK3β) was discovered as a major factor in glucose homeostasis. GSK3β is a pivotal regulator of glycogen synthesis by altering the activity of glycogen synthase and perturbation in this process have been linked to at l
Autor:
Steen B. Pedersen, S. B. Haugaard, J. J. Holst, Johan Iversen, Ole Kæseler Andersen, Flemming Dela, Carolyn F. Deacon, Sten Madsbad
Publikováno v:
HIV Medicine. 7:163-172
Objectives We examined whether insulin-resistant lipodystrophic HIV-infected patients with known high fasting prehepatic insulin secretion rates (FISRs) displayed alterations in first-phase prehepatic insulin response to intravenous glucose (ISREG0
Autor:
Ulrik B. Andersen, Allan Flyvbjerg, Sten Madsbad, Hans Ørskov, Johan Iversen, S. B. Haugaard, J. O. Nielsen, Ole Kæseler Andersen
Publikováno v:
European Journal of Clinical Investigation. 34:561-568
Treatment with high doses (2-6 mg day(-1)) of human growth hormone (hGH) in patients with human immunodeficiency virus (HIV)-associated lipodystrophy syndrome (HALS) has been shown to increase concentrations of total insulin-like growth-factor-I (IGF
Autor:
C. Anholm, P. Kumarathurai, M. S. Klit, O. P. Kristiansen, O. W. Nielsen, S. Ladelund, S. Madsbad, A. Sajadieh, S. B. Haugaard, C. Lange, J. J. Holst, J. Molvig, C. Deacon, M. Fenger, O. Andersen, R. Boston
Publikováno v:
BMJ Open
Introduction Newly diagnosed type 2 diabetes mellitus (T2DM) in patients with coronary artery disease (CAD) more than doubles the risk of death compared with otherwise matched glucose tolerant patients. The biguanide metformin is the drug of choice i
Autor:
S B, Haugaard, O, Andersen, T W, Hansen, J, Eugen-Olsen, A, Linneberg, S, Madsbad, M H, Olsen, T, Jørgensen, K, Borch-Johnsen, J, Jeppesen
Publikováno v:
Diabetic medicine : a journal of the British Diabetic Association. 29(4)
To explore the putative association of new-onset diabetes and the soluble urokinase plasminogen activator receptor (suPAR), which is a new and stable plasma marker of immune function and low-grade inflammation. This association has been previously su
Autor:
J, Eugen-Olsen, O, Andersen, A, Linneberg, S, Ladelund, T W, Hansen, A, Langkilde, J, Petersen, T, Pielak, L N, Møller, J, Jeppesen, S, Lyngbaek, M, Fenger, M H, Olsen, P R, Hildebrandt, K, Borch-Johnsen, T, Jørgensen, S B, Haugaard
Publikováno v:
Journal of internal medicine. 268(3)
Low-grade inflammation is thought to contribute to the development of cardiovascular disease (CVD), type-2 diabetes mellitus (T2D), cancer and mortality. Biomarkers of inflammation may aid in risk prediction and enable early intervention and preventi
Autor:
T. Almdal, Rasmus Rabøl, S. B. Haugaard, Robert Boushel, Patricia V. Højberg, Flemming Dela, Sten Madsbad
Publikováno v:
Diabetes, obesitymetabolism. 11(4)
Aim: Several mechanisms have been targeted as culprits of weight gain during antihyperglycaemic treatment in type 2 diabetes (T2DM). These include reductions in glucosuria, increased food intake from fear of hypoglycaemia, the anabolic effect of insu